With the emerging success of treating CD19 expressing B cell malignancies with ex vivo modified, autologous T cells that express CD19-directed chimeric antigen receptors (CAR), there is intense interest in expanding this evolving technology to develop effective modalities to treat other malignancies including solid tumors. Exploiting this approach to develop a therapeutic modality for T cell malignancies for which the available regimens are neither curative, nor confer long term survival we generated a lentivirus-based CAR gene transfer system to target the chemokine receptor CCR4 that is over-expressed in a spectrum of T cell malignancies as well as in 
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| I N T R O D U C T I O N
The chemokine receptor CCR4 is a seven trans-membrane G proteincoupled cell surface receptor molecule (alternatively designated CD194) with selective expression on cells of the hematopoietic system (reviewed in Refs. 1,2). In the peripheral blood of healthy individuals, CD4 1 CD25 1 Foxp31 T regulatory (Treg) cells, T H2 and T H17 T cells, as well as platelets display a preponderance of CCR4 expression. [3] [4] [5] [6] [7] [8] Although initial reports have suggested some level of promiscuity in CCR4 ligand specificity, it is now validated that the C-C chemokines CCL17 and CCL22 are the only, high affinity ligands of this receptor. [9] [10] [11] The aberrant over-expression of CCL17 and CCL22 especially by stromal cells that is seen in a variety of neoplasms including, breast, ovarian, gastric, and esophageal cancers and in lymphoid malignancies such as Hodgkin's disease [12] [13] [14] [15] [16] [17] is the primary driver for the extensive influx of CCR4 bearing Tregs into the tumor micro-environment of such malignancies that not only impede effective anti-tumor immune responses, but also promote tumor trafficking and metastasis as well. 18 In adult T cell leukemia (ATL), an HTLV-1 associated T cell malignancy that some consider to be a CD41 Treg disorder, the cell-surface expression of CCR4 on leukemic cells is near universal. 19, 20 Moreover, in a majority of cutaneous T cell lymphomas [peripheral T-cell lymphoma (PTCL)/cutaneous T-cell lymphoma (CTCL), Mycosis Fungoides (MF)/Sezary syndrome (SS)], the homing of malignant cells to the skin is primarily dictated by the cell-surface-expressed CCR4. 21, 22 A significant proportion of anaplastic large cell lymphomas (ALCL), and other peripheral T-cell lymphomas also express CCR4 receptors perhaps as a consequence of the aberrant expression of the T H 2 master transcriptional regulator GATA-3 in these tumors and the presence of CCR4 in these tumors has shown to be an independent prognostic factor of poor survival in both peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and anaplastic lymphoma kinase (ALK) negative ALCL by a multivariate analysis. [23] [24] [25] [26] Mogamulizumab is a defucosylated humanized antibody engineered to exert enhanced antibody-dependent cytotoxicity that targets CCR4
and is approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma 27 and accumulating evidence reveals considerable efficacy of this modality even in heavily pretreated patients. 28 The observed adverse events are primarily of hematologic nature in addition to pyrexia and skin disorders that are manageable and are also reversible. 28, 29 Equally important, mogamulizumab therapy also selectively depletes effector type CD4 1 Foxp31 Tregs resulting in the induction of heightened anti-tumor responses in the treated patients. 30, 31 Taking a different approach, we have developed a lentiviral gene transfer system to genetically engineer autologous T cells to express a chimeric antigen receptor (CAR) that targets CCR4 using humanized variable heavy (VH) and kappa light (VL) chain moieties derived from an anti-CCR4 antibody that is different from mogamulizumab. 32 
| M E T H O D S
2.1 | Construction of CCR4 chimeric antigen receptor and lentiviral stock preparation
Humanization of anti-human CCR4 monoclonal antibody 1567 and its affinity matured variant mAb2-3 has been previously reported 32 along with the amino acid sequence of the variable heavy (VH) and variable light (VL) kappa domains of mAb2-3 and these sequences were utilized in the construction of our CCR4 CAR construct and its molecular configuration is depicted in Figure 1A . The amino acid sequences of CD8 hinge and transmembrane domain, 4-1BB (CD137) signaling module, The CCR4 CAR lentiviral pellet was then dissolved in a volume of PBS to achieve a 1000-fold concentration, and stored at 2808C until used.
| Cells and culture conditions
The 
| T cell transduction
A Pan-T cell isolation kit (Miltenyi Biotec) was used to purify untouched T cells from human peripheral blood mononuclear cells and the cells were then activated in the presence of 30 IU/ml IL-2 by adding Dynabeads T activator CD3/CD28 beads (Life Technologies) at three beads per 1 cell ratio for 48 hours. A retronectin-coated dish (Takara Bio) was first pre-centrifuged for 2 hours at 2000g after adding CCR4 CAR lentiviral particles to adsorb lentiviral particles to the plate surface at 328C2358C and the activated T cells (1 3 10) 6 were then added into the dish. The IL-2 concentration in the culture medium was then increased to 300 IU/ml and the cells were expanded at 378C
by feeding with fresh medium every 2 days while maintaining a cell density around 1-3 3 10 6 cells/ml.
| Flow cytometry
For immunophenotyping CCR4 CAR transduced T cells, one million cells were stained with CD4-PerCP, CD8-APC or Protein L-Biotin (Thermo Scientific) as has been described previously. 34 The presence of cell surface-bound Protein L was detected with SA-PerCP or SA-PE.
| Cellular cytotoxicity
The cytotoxic effector activity of CCR4 CAR T cells was determined either using a standard 4-hour 51 Cr release assay 35 or a biophotonic cytotoxicity assay 36 using the ATL41214 cell line and measuring bioluminescence with the addition of D-luciferin (0.14 mg/ml final concentration per well from Xenogen) at the indicated time points using a microplate counter (PerkinElmer). Percent specific lysis was calculated using the following formula for the biophotonic assay:
2.6 | Cell proliferation assay 
| R E S U LTS
The structural configuration of our CAR molecule is depicted in Figure   1A which consists of a transmembrane module derived from the human CD8 molecule along with two intracellular signaling modules derived from 4-1BB (CD137) and CD3ʓ in addition to the extracellular CCR4-binding domains derived from a humanized anti-CCR4 antibody.
We transduced donor derived, activated CD31 T cells once and routinely achieved over 80% transduction efficiency as determined by Figure 2C ). In contrast, no cytolytic activity was observed when CCR4 CAR T cells were co-cultured with BJAB cells.
However, BJAB/CCR4 cells that stably express human CCR4 manifested sensitivity to CCR4 CAR T cell mediated cytolysis thus validating the robust functionality and specificity of our CCR4 CAR ( Figure 2D ).
To assess the broader utility of the CCR4-directed CAR approach, We also measured the CCR4 mRNA levels in these cell lines by quantitative PCR (TaqMan). CCR4 mRNA levels in some cell lines were extremely high while in others, the levels were relatively low (Supporting Information Table 1 ) and we observed a better correlation between lytic susceptibility and CCR4 mRNA levels than with cell surface CCR4 unraveling the pathogenesis as well as devising novel efficacious therapeutic strategies for most T-cell malignancies. 40 With gene expression profiling, it has been recently established that nearly half of PTCL-NOS, a diverse group that accounts for about 50% of PTCL, lack any classifiable markers but over-express the T H 2 master transcriptional regulator GATA-3 and often carry a poor prognosis. 24, 25 As in normal T H 2 CD41
T lymphocytes, GATA-3 drives the transcription of CCR4 in these PTCL-NOS and consequently they over-express cell surface CCR4. 41 Moreover, recent assessments of mutational landscapes in CTCL, Sezary syndrome and ATL have revealed genetic aberrations of the chromosome 10p to be a shared feature in these T cell malignancies with the inactivation of ZEB1 resulting in the enhanced expression of GATA3. [42] [43] [44] [45] In addition to GATA3 driven transcription of CCR4 gene, frequent mutations in the C-terminus of CCR4 polypeptide in PTCL-NOS, CTCL and ATL impair the ligand induced receptor internalization of CCR4 thereby contributing to its cell surface over-expression in these malignant cells as well. 33, 43, 46, 47 The oncogenic transcription factor FRA-2 has also been implicated in the over-expression of CCR4 in both CTCL and ATL. 48, 49 As almost all CTCL and ATL also overexpress CCR4, as well as a large fatality have been observed. 53 However, as mentioned earlier, in the trials conducted by Duvic et al. 29 and Ogura et al., 28 the hematologic adverse effects of magamulizumab were minimal and/or manageable.
Collectively, despite these concerns the tantalizing promise that CCR4
CAR could be exploited to effectively treat T-cell malignancies, have convinced us that a nonhuman primate study is essential prior to undertaking clinical studies in patients. The extracellular domains of rhesus macaque CCR4 is 100% identical to that of human CCR4 54 and the antibody from which our CCR4 CAR was derived reacts with nonhuman primate CCR4 55 thereby allowing us to conduct an evaluative safety study in rhesus macaques with ex-vivo engineering of monkey CD31 T cells with our CCR4 CAR and reinfusion of the autologous modified T cells back into the animals to uncover any potential on target but off tumor toxicities that might arise in a clinical trial of CCR4-positive T cell malignancies. In conclusion, we are cautiously optimistic PERERA ET AL.
